STOCK TITAN

Enlivex’s Allocetra knee trial can keep enrolling

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Enlivex Ltd. said the independent Data and Safety Monitoring Board completed an interim safety review of 85 patients randomized and dosed in its Allocetra Phase IIb knee osteoarthritis trial. The board confirmed that the treatment’s safety profile allows enrollment to continue as planned.

The randomized, double-blind, placebo-controlled global study is planned to enroll approximately 182 patients aged 64 and older at clinical centers in the United States, Denmark and Poland. It evaluates three intra-articular injections; key efficacy endpoints compare changes in pain and physical function with placebo at three and six months after treatment.

Patients in interim safety review 85 patients Randomized and dosed in the Phase IIb trial
Planned trial enrollment Approximately 182 patients Phase IIb knee osteoarthritis trial
Allocetra injections 3 intra-articular injections Trial regimen being evaluated
Minimum patient age 64 years Trial eligibility includes patients aged 64 and older
Efficacy assessment timepoints 3 and 6 months Following treatment; pain and physical function compared with placebo
Follow-up period 1 year Additional trial endpoint follow-up
Data and Safety Monitoring Board medical
"independent Data and Safety Monitoring Board (DSMB)"
An independent panel of experts that watches over a clinical trial to protect participants and ensure the data are reliable, acting like an impartial referee who can recommend pausing or stopping the study if safety problems or clear benefits emerge. Investors care because the board’s findings can change a drug or device’s timeline, cost, and odds of regulatory approval, directly affecting a company’s value and risk profile.
randomized, double-blind, placebo-controlled medical
"randomized, double-blind, placebo-controlled Phase IIb trial"
A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.
intra-articular injections medical
"designed to evaluate efficacy and safety of 3 intra-articular injections"
Intra-articular injections are treatments where medication or other therapeutic agents are injected directly into a joint space, like putting oil straight into a car hinge to reduce friction. For investors, they matter because they represent a targeted way to treat joint pain or disease that can reduce side effects and sometimes improve outcomes, influencing a product’s clinical appeal, market demand, regulatory pathway, and potential revenue.
primary knee osteoarthritis medical
"patients 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis"
topline data medical
"look forward to reporting topline data"
Topline data are the initial, high-level results from a clinical study that show whether the main goals of the trial were met, much like the headline of a news story that summarizes the most important point. Investors care because these early outcomes quickly indicate a drug’s commercial potential and regulatory path — positive topline results can boost a company’s value, while disappointing ones can sharply reduce expected future revenue.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the DSMB conclude about Enlivex (ENLV)’s Allocetra trial?

It said the safety profile allows enrollment to continue as planned. The interim review covered data from 85 patients randomized and dosed.

How many patients is Enlivex (ENLV) planning to enroll in its Phase IIb knee osteoarthritis trial?

Approximately 182 patients are planned for enrollment. The trial is designed to evaluate three intra-articular injections of Allocetra in patients aged 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis.

When will the Enlivex (ENLV) trial assess pain and physical function?

At three and six months following treatment, the trial will measure changes from baseline in pain and physical function compared with placebo.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: November 2026

 

Commission file number: 001-36578

 

ENLIVEX LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

On November 18, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), issued a press release announcing that the independent Data and Safety Monitoring Board overseeing the Company's randomized, double-blind, placebo-controlled Phase IIb trial evaluating Allocetra™ in patients with primary age-related knee osteoarthritis has completed an interim safety review of data from 85 patients randomized and dosed in the trial. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Exhibit No.  
   
99.1 Press Release

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Enlivex Ltd.
  (Registrant)
   
  By: /s/ Oren Hershkovitz
 

Name: 

Title:

Oren Hershkovitz
Chief Executive Officer

 

Date: November 18, 2026

 

2

 

Exhibit 99.1

 

Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial

 

Nes-Ziona, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s randomized, double-blind, placebo-controlled Phase IIb trial evaluating Allocetra™ in patients with primary age-related knee osteoarthritis has completed an interim safety review of data from 85 patients randomized and dosed in the trial. Following review of the data, the DSMB confirmed that the safety profile of Allocetra™ allows the Company to continue enrolling patients in the trial as planned.

 

“The outcome of this interim review, covering 85 patients randomized and dosed in the trial, appears consistent with the favorable safety profile observed in our Phase I/IIa trial,” said Einat Galamidi, Chief Medical Officer of Enlivex. “We are pleased with the DSMB’s decision that the trial will continue as planned and designed, and we remain focused on executing the Phase IIb trial and look forward to reporting topline data.”

 

About the Phase IIb Trial

 

The Phase IIb trial (NCT07580716), is a randomized, double-blind, placebo-controlled, global, multicenter, clinical trial which is designed to evaluate the efficacy and safety of 3 intra-articular injections of Allocetra™ in patients 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis. The trial is planned to enroll approximately 182 patients from clinical centers in the United States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo, measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures, functional mobility assessments and one year follow-up.

 

About Knee Osteoarthritis

 

Osteoarthritis (OA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to continue to grow substantially, with knee OA (KOA) being the most prevalent form. There are currently no approved disease-modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of KOA patients are 60 years of age or older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.

 

About Enlivex

 

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain Protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

 

 

 

 

Forward-looking statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

 

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that results from subgroup analyses and small patient populations, including those described in this press release, may not be replicated in larger trials, including the Company’s ongoing Phase IIb trial; the risk that topline data may change following a more comprehensive review of the data; the risk that RMAT designation may not lead to a faster development or regulatory review process and does not increase the likelihood of approval; risks related to the timing, conduct and outcome of clinical trials and regulatory submissions; the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

 

Enlivex contact

 

Shachar Shlosberger

CFO

Enlivex Ltd.

shachar@enlivex.com

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading